Laurent Fischer - 05 Dec 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
CEO, PRESIDENT AND DIRECTOR, Director
Signature
/s/ Aneta Fergson, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
05 Dec 2025
Transactions value $
$553,917
Form type
4
Filing time
08 Dec 2025, 21:45:06 UTC
Previous filing
27 Jun 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fischer Laurent CEO, PRESIDENT AND DIRECTOR, Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY /s/ Aneta Fergson, Attorney-in-Fact 08 Dec 2025 0001379344

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Purchase $47K +11.1K +15.22% $4.24 83.9K 05 Dec 2025 Direct F1, F2
transaction ADVM Common Stock Purchase $507K +118K +140.19% $4.31 202K 08 Dec 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.21 to $4.25. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2 Includes 600 shares purchased on May 21, 20125 and 600 shares purchased on November 20, 2025, pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.
F3 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.25 to $4.32. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.